Johnson & Johnson (JNJ)
Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K
The plaintiff used J&J's baby powder from 1969 until 2017. She sued in 2019 and died six months later at the age of 68.
Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial
A jury in Pennsylvania state court on Friday awarded $250,000 to the family of a woman who sued Johnson & Johnson alleging its talc-based baby powder was to blame for her ovarian cancer, according to an attorney for plaintiffs in nationwide talc litigation against the company.
After A 55% Surge, Is JNJ Stock Still A Buy?
Johnson & Johnson (JNJ) stock is currently at a notable juncture. It exhibits strong momentum, up 55% in the last twelve months, and investing in it entails support for a company characterized by robust margins, healthy cash flow, a low-debt capital structure, and favorable market conditions.
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent Loss
Johnson & Johnson JNJ has one of the most diverse revenue streams in the industry within its pharmaceuticals division, called Innovative Medicine. The company has several multi-million-dollar drugs covering a broad range of areas such as neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary hypertension (PH) and infectious diseases.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
What's Behind The 50% Surge In JNJ Stock?
In the nearly nine months spanning from May 2025 to February 2026, Johnson & Johnson (JNJ)'s stock experienced a remarkable 52% increase, driven by improved earnings, significant product achievements, and advancements in legal matters. Behind this 3.2% uplift in revenue and enhancement in margins is a narrative of innovation, effective risk management, and strategic evolution—let's delve into what has influenced this change.
Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over
Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over
US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy
A U.S. district judge on Thursday dismissed a lawsuit alleging Johnson & Johnson committed fraud by repeatedly attempting to use a shell company's bankruptcy to resolve tens of thousands of lawsuits claiming its baby powder and other talc products caused cancer.
Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?
JNJ beat Q4 expectations and guided 2026 sales to be in the range of $100-$101B, with Innovative Medicine and MedTech growth offsetting Stelara LOE.
Johnson & Johnson: Strong Momentum Heading Into 2026
Johnson & Johnson remains a buy as business momentum accelerates, with Q4 revenue up 9.1% YoY and strong U.S. sales resilience. Their deal with the Trump Administration eliminates tariffs in exchange for lower drug prices. This is expected to provide gross margin relief despite some remaining pressure. Guidance for 2026 calls for accelerating top-line growth and at least 50bps pre-tax operating margin expansion. They also have longer-term double-digit growth ambitions.
J&J Targets $100B+ Sales in 2026 as Growth Accelerates in Both Units
On its fourth-quarter earnings conference call on Jan. 21, Johnson & Johnson JNJ announced its financial outlook for 2026, which exceeded consensus expectations.
